This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Piccart, M. J. Articles by Pecorelli, S. Search for Related Content PubMed PubMed Citation Articles by Piccart, M. J. Articles by Pecorelli, S. Social Bookmarking                            What's this?

Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group

From the Institut Jules Bordet and European Organization for Research and Treatment of Cancer, Brussels; Universitaire Ziekenhuis Gasthuisberg, Leuven, Belgium; Clatterbridge Hospital, Bebington; Western Infirmary, Glasgow, United Kingdom; Hospital General de Asturias, Oviedo; Universidad Hospital 12 de Octubre, Madrid, Spain; Libera Universita "Campus Bio-Medico," Rome; Ospedale Civile Maggiore, Verona; Spedali Civili di Brescia, Brescia, Italy; Instituto Portugues, Lisbon, Portugal; and Debiopharm, Lausanne, Switzerland.

Address reprint requests to M.J. Piccart, MD, Institut Jules Bordet, 1 rue Héger Bordet, 1000 Bruxelles, Belgique; email mpiccart{at}ulb.ac.be

PURPOSE: This was a multicentric, open, randomized, phase II study of single-agent paclitaxel and oxaliplatin to evaluate the efficacy of oxaliplatin in a relapsing progressive ovarian cancer patient population and to analyze the safety profile and impact of both agents on quality of life, time to progression, and survival.

PATIENTS AND METHODS: Eighty-six patients with platinum-pretreated advanced ovarian cancer were randomly assigned to two arms: 41 received paclitaxel at 175 mg/m² over 3 hours every 3 weeks, and 45 received oxaliplatin at 130 mg/m² over 2 hours every 3 weeks. For inclusion, patients had to have a performance status of 0 to 2 and to have received at least one and no more than two prior cisplatin- and/or carboplatin-containing chemotherapy regimens within the last 12 months.

RESULTS: Seven confirmed responses were observed in each arm, for an overall response rate in the total treated population of 17% (95% confidence interval [CI], 7% to 32%) in the paclitaxel arm and 16% (95% CI, 7% to 29%) in the oxaliplatin arm. Median time to progression was 14 weeks and 12 weeks, and overall survival was 37 weeks and 42 weeks in the paclitaxel and oxaliplatin arms, respectively. Among 63 patients with a 0- to 6-month progression-free, platinum-free interval, there were five objective responses with paclitaxel in 31 patients and two objective responses with oxaliplatin in 32 patients. Nine patients (22%) in the paclitaxel arm had grade 3 or 4 neutropenia (National Cancer Institute of Canada [NCIC] Common Toxicity Criteria). Two patients (4%) experienced grade 3 thrombocytopenia in the oxaliplatin arm. Maximum grade (grade 3) NCIC neurosensory toxicity was experienced by three patients (7%) in the paclitaxel arm and by four patients (9%) in the oxaliplatin arm.

CONCLUSION: Single-agent oxaliplatin at 130 mg/m² every 3 weeks is active with moderate toxicity in patients with cisplatin-/carboplatin-pretreated advanced ovarian cancer.

Presented at the Twenty-Third Congress of the European Society for Medical Oncology, Athens, Greece, November 6-10, 1998, and, in part, at the Thirty-Fourth Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, May 16-20, 1998.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. M. Del Campo, A. Roszak, M. Bidzinski, T. E. Ciuleanu, T. Hogberg, M. Z. Wojtukiewicz, A. Poveda, K. Boman, A. M. Westermann, C. Lebedinsky, et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer Ann. Onc., June 25, 2009; (2009) mdp198v1. [Abstract] [Full Text] [PDF]

				P. J. Hoskins Triple Cytotoxic Therapy for Advanced Ovarian Cancer: A Failed Application, Not a Failed Strategy J. Clin. Oncol., March 20, 2009; 27(9): 1355 - 1358. [Full Text] [PDF]

				D. G. Mutch, M. Orlando, T. Goss, M. G. Teneriello, A. N. Gordon, S. D. McMeekin, Y. Wang, D. R. Scribner Jr, M. Marciniack, R. W. Naumann, et al. Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2811 - 2818. [Abstract] [Full Text] [PDF]

				P. Viens, T. Petit, A. Yovine, P. Bougnoux, G. Deplanque, P.-H. Cottu, R. Delva, J.-P. Lotz, S. V. Belle, J.-M. Extra, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients Ann. Onc., March 1, 2006; 17(3): 429 - 436. [Abstract] [Full Text] [PDF]

				P. M. Fracasso, J. A. Blessing, M. A. Morgan, A. K. Sood, and J. S. Hoffman Phase II Study of Oxaliplatin in Platinum-Resistant and Refractory Ovarian Cancer: A Gynecologic Group Study J. Clin. Oncol., August 1, 2003; 21(15): 2856 - 2859. [Abstract] [Full Text] [PDF]

				D. Mavroudis, P. Pappas, C. Kouroussis, S. Kakolyris, S. Agelaki, K. Kalbakis, N. Androulakis, J. Souglakos, N. Vardakis, M. Nikolaidou, et al. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors Ann. Onc., February 1, 2003; 14(2): 304 - 312. [Abstract] [Full Text] [PDF]

				S. Cascinu, V. Catalano, L. Cordella, R. Labianca, P. Giordani, A. M. Baldelli, G. D. Beretta, E. Ubiali, and G. Catalano Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Oncol., August 15, 2002; 20(16): 3478 - 3483. [Abstract] [Full Text] [PDF]

				V. Dieras, P. Bougnoux, T. Petit, P. Chollet, P. Beuzeboc, C. Borel, F. Husseini, A. Goupil, P. Kerbrat, J. L. Misset, et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin {+/-} taxane-pretreated ovarian cancer patients Ann. Onc., February 20, 2002; 13(2): 258 - 266. [Abstract] [Full Text] [PDF]

				M. Seiden Highlights in Ovarian Cancer Oncologist, August 1, 2000; 5(4): 267 - 273. [Abstract] [Full Text]